Overview

Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Study to investigate the pharmacokinetic drug-drug interaction potential of BI 207127 NA and BI 201335 NA on each other at steady-state and to quantify the effect of BI 207127 NA, and BI 207127 NA combined with BI 201335 NA, on the activity of CYP 2C9 and CYP 3A4 using the probe substrates tolbutamide (CYP 2C9) and midazolam (CYP 3A4).

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Midazolam
Tolbutamide